Developers anticipate releasing full efficacy results from the phase 2 THIO-101 trial later this year. With a data cutoff date of August 1, 2024, 16 patients had a survival follow-up period of more ...
CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for ...
Selected dose shows unprecedented disease control and overall response rates in a NSCLC clinical trial CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical stage company developing telomere-targeting immunotherapies for cancer, today announced positive results from an ...
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results